# Chapter 6: Tumor Suppressor Genes

## 6.1 Discovery and Function of Tumor Suppressor Genes

Tumor suppressor genes encode proteins that restrain cell growth, promote differentiation, regulate apoptosis, and maintain genomic integrity. Unlike oncogenes, which drive cancer through their activation, tumor suppressor genes contribute to cancer when their normal function is lost. Their discovery and characterization have been pivotal in our understanding of cancer biology and have provided critical insights into potential therapeutic approaches.

### 6.1.1 Historical Perspective and Discovery

The concept of tumor suppressor genes emerged gradually through converging lines of evidence from cell fusion experiments, epidemiological studies of hereditary cancers, and cytogenetic analyses.

**Cell Fusion Studies**

In the 1960s and 1970s, Henry Harris and colleagues performed groundbreaking experiments involving the fusion of normal cells with cancer cells. These studies revealed that:

- When normal cells and malignant cells were fused to create hybrid cells, the resulting hybrids often displayed a non-tumorigenic phenotype.
- This suggested that normal cells contained factors that could suppress the malignant properties of cancer cells.
- When the hybrids eventually regained tumorigenic potential, they had typically lost specific chromosomes from the normal cell parent, suggesting that the tumor-suppressive factors were encoded by genes on these chromosomes.

These cell fusion experiments provided the first functional evidence for the existence of genes that could suppress malignancy, challenging the prevailing oncogene-centric view of cancer development.

**Hereditary Cancer Syndromes**

Epidemiological studies of familial cancer syndromes provided complementary evidence for tumor suppressor genes:

- Alfred Knudson studied retinoblastoma, a rare childhood eye tumor, and noticed that it occurred in both hereditary and sporadic forms.
- In 1971, Knudson proposed his "two-hit hypothesis" based on statistical analysis of retinoblastoma cases:
  - Hereditary cases typically developed bilateral, multifocal tumors at an early age
  - Sporadic cases were usually unilateral and occurred later
  - Knudson proposed that two mutational events (hits) were required for tumor development
  - In hereditary cases, the first hit was inherited in all cells, requiring only one somatic mutation for tumor formation
  - In sporadic cases, both hits had to occur somatically in the same cell, a statistically rarer event

Knudson's hypothesis provided a framework for understanding how cancer predisposition could be inherited in a dominant manner at the familial level while requiring recessive inactivation at the cellular level.

**Isolation of the First Tumor Suppressor Genes**

The retinoblastoma gene (RB1) was the first tumor suppressor gene to be molecularly characterized:

- In the early 1980s, cytogenetic studies identified deletions in chromosome 13q14 in retinoblastoma tumors.
- In 1986, Thaddeus Dryja, Stephen Friend, and Robert Weinberg isolated the RB1 gene.
- They demonstrated that both alleles of RB1 were inactivated in retinoblastoma tumors, consistent with Knudson's two-hit hypothesis.
- Subsequent functional studies confirmed that reintroduction of the wild-type RB1 gene into retinoblastoma cells suppressed their tumorigenic properties.

Following the identification of RB1, other tumor suppressor genes were characterized:

- TP53, identified in 1979 as a protein interacting with SV40 large T antigen, was initially misclassified as an oncogene before being recognized as a tumor suppressor in the late 1980s.
- APC, responsible for familial adenomatous polyposis, was identified in 1991.
- BRCA1 and BRCA2, associated with hereditary breast and ovarian cancer, were identified in 1994 and 1995, respectively.
- PTEN, involved in Cowden syndrome and sporadic cancers, was identified in 1997.

The molecular identification of these and other tumor suppressor genes validated the concept that cancer could arise not only from the activation of oncogenes but also from the inactivation of genes that normally restrain cell growth and maintain genetic stability.

**Genomic Approaches to Tumor Suppressor Identification**

Advances in genomic technologies have dramatically accelerated the identification of tumor suppressor genes:

- Comparative genomic hybridization (CGH) and single nucleotide polymorphism (SNP) arrays enabled the detection of recurrent deletions in cancer genomes.
- Next-generation sequencing revealed the landscape of mutations across cancer types, highlighting genes that are recurrently inactivated.
- Functional genomic screens using RNA interference or CRISPR-Cas9 technology have identified genes whose loss promotes cancer phenotypes.
- Integrative analyses combining genomic, transcriptomic, and epigenomic data have uncovered tumor suppressors that are silenced through various mechanisms.

These approaches have expanded our catalog of tumor suppressor genes beyond the classical examples identified through hereditary cancer syndromes, revealing a complex network of growth-constraining genes that are targeted in cancer.

### 6.1.2 General Functions of Tumor Suppressor Genes

Tumor suppressor genes encode proteins with diverse functions that collectively maintain cellular homeostasis and prevent uncontrolled growth. Their roles can be broadly categorized into several functional groups:

**Cell Cycle Regulation**

Many tumor suppressors control cell cycle progression, preventing inappropriate cell division:

- **RB (Retinoblastoma protein)**: Controls the G1/S transition by sequestering E2F transcription factors until appropriately phosphorylated by cyclin-dependent kinases (CDKs).
- **p16INK4A (CDKN2A)**: Inhibits CDK4/6, preventing phosphorylation of RB and cell cycle progression.
- **p21CIP1 (CDKN1A)**: Broad-spectrum CDK inhibitor activated by p53 in response to DNA damage.
- **p27KIP1 (CDKN1B)**: Inhibits cyclin E-CDK2 and cyclin A-CDK2 complexes, regulating progression through G1 and S phases.

These cell cycle regulators ensure that cells divide only under appropriate conditions, with adequate resources and in the absence of DNA damage or other cellular stresses.

**DNA Damage Response and Repair**

Several tumor suppressors monitor genomic integrity and coordinate responses to DNA damage:

- **p53 (TP53)**: The "guardian of the genome," activates cell cycle arrest, DNA repair, or apoptosis in response to various cellular stresses, including DNA damage.
- **BRCA1 and BRCA2**: Critical for homologous recombination repair of double-strand breaks.
- **ATM and ATR**: Kinases that sense DNA damage and initiate signaling cascades to coordinate repair and cell cycle checkpoints.
- **CHEK1 and CHEK2**: Checkpoint kinases that propagate DNA damage signals.
- **MLH1, MSH2, and other mismatch repair proteins**: Correct errors introduced during DNA replication.

By maintaining genomic integrity, these tumor suppressors prevent the accumulation of mutations that could lead to oncogene activation or inactivation of other tumor suppressors.

**Apoptosis Regulation**

Tumor suppressors often promote programmed cell death when cells are damaged beyond repair or receive inappropriate growth signals:

- **p53**: Induces expression of pro-apoptotic genes (e.g., BAX, PUMA, NOXA) in response to severe cellular stress.
- **PTEN**: Negatively regulates the PI3K-AKT pathway, which promotes cell survival.
- **APAF1**: Component of the apoptosome involved in the intrinsic apoptotic pathway.
- **Death receptors (e.g., FAS) and their signaling components**: Mediate the extrinsic apoptotic pathway.

These apoptosis regulators ensure the elimination of cells that could otherwise accumulate mutations and become cancerous.

**Cell Adhesion and Tissue Architecture**

Some tumor suppressors maintain tissue integrity by regulating cell-cell and cell-matrix interactions:

- **E-cadherin (CDH1)**: Mediates epithelial cell-cell adhesion, maintaining tissue architecture.
- **APC**: Besides its role in WNT signaling, contributes to cell adhesion and migration.
- **NF2 (Merlin)**: Links cell surface receptors to the cytoskeleton, regulating contact inhibition.
- **FAT family cadherins**: Involved in cell adhesion and Hippo pathway regulation.

By preserving tissue architecture, these tumor suppressors prevent cells from detaching, migrating, and invading—processes essential for metastasis.

**Signal Transduction Regulation**

Many tumor suppressors negatively regulate growth-promoting signaling pathways:

- **PTEN**: Dephosphorylates PIP3, antagonizing PI3K signaling.
- **NF1**: Enhances the GTPase activity of RAS, inactivating RAS-MAPK signaling.
- **TSC1/TSC2 complex**: Inhibits mTORC1, a central regulator of cell growth and protein synthesis.
- **PTPN11 and other protein tyrosine phosphatases**: Counteract the activity of receptor and non-receptor tyrosine kinases.

These negative regulators ensure that proliferative signaling occurs only in response to appropriate stimuli and is properly terminated.

**Metabolism Regulation**

Some tumor suppressors influence cellular metabolism, countering the metabolic reprogramming characteristic of cancer cells:

- **p53**: Regulates mitochondrial respiration, glycolysis, and glutaminolysis.
- **LKB1 (STK11)**: Activates AMPK, a central metabolic sensor that promotes catabolic processes under energy stress.
- **PTEN and TSC1/TSC2**: Regulate mTORC1, which coordinates cell growth with nutrient availability.
- **FH (Fumarate hydratase) and SDH (Succinate dehydrogenase)**: TCA cycle enzymes whose loss leads to accumulation of oncometabolites.

These metabolic regulators prevent the aerobic glycolysis (Warburg effect) and other metabolic alterations that support the high biosynthetic demands of cancer cells.

**Epigenetic Regulation**

Some tumor suppressors function through epigenetic mechanisms to maintain proper gene expression patterns:

- **RB and related pocket proteins**: Interact with histone-modifying enzymes to establish repressive chromatin at cell cycle genes.
- **SMARCB1/SNF5 and other SWI/SNF complex components**: Participate in ATP-dependent chromatin remodeling.
- **DNMT3A and TET family enzymes**: Regulate DNA methylation patterns.
- **MLL family proteins and other histone modifiers**: Maintain appropriate histone modification landscapes.

These epigenetic regulators ensure the stable expression of differentiation programs and the repression of genes that could promote cellular transformation.

**Stemness and Differentiation**

Some tumor suppressors promote cellular differentiation and limit stem cell-like properties:

- **APC**: Regulates WNT signaling, which is critical for stem cell maintenance in various tissues.
- **NOTCH pathway components**: Control cell fate decisions and differentiation.
- **p53**: Promotes differentiation in various cellular contexts.
- **RB**: Interacts with lineage-specific transcription factors to regulate differentiation.

By promoting differentiation, these tumor suppressors limit the self-renewal capacity that is often reactivated in cancer cells.

**Immune Surveillance**

Emerging evidence suggests that some tumor suppressors enhance immune recognition and elimination of potential cancer cells:

- **p53**: Regulates expression of genes involved in innate immunity and inflammation.
- **PTEN**: Influences the tumor microenvironment and immune cell function.
- **MHC class I and components of the antigen presentation machinery**: Enable recognition of aberrant cells by cytotoxic T lymphocytes.

These immunoregulatory functions contribute to the elimination of transformed cells before they can establish clinically detectable tumors.

The diverse functions of tumor suppressor genes reflect the multiple barriers that must be overcome during malignant transformation. The specific tumor suppressors targeted in a given cancer type often reflect the particular selective pressures and vulnerabilities of the cell of origin.

### 6.1.3 Cellular Context and Tissue Specificity

The functions and importance of tumor suppressor genes can vary dramatically depending on cellular context and tissue type, contributing to the tissue-specific patterns of tumor suppressor inactivation observed in different cancer types.

**Tissue-Specific Expression and Function**

Many tumor suppressor genes show tissue-specific patterns of expression and function:

- **APC**: Particularly critical in intestinal epithelium, where it regulates WNT signaling to control stem cell homeostasis.
- **VHL**: Especially important in renal epithelium, where it regulates the hypoxia-inducible factor (HIF) pathway.
- **BRCA1/2**: While expressed broadly, their loss particularly predisposes to breast and ovarian cancers, suggesting tissue-specific vulnerabilities.
- **NF1**: Affects multiple tissues but shows particularly strong tumor suppressor activity in Schwann cells, explaining the predominance of neurofibromas in neurofibromatosis type 1.

These tissue-specific patterns reflect differences in the signaling pathways and cellular processes that maintain homeostasis in different tissues.

**Cell Type-Specific Dependencies**

Even within a single tissue, different cell types may depend on different tumor suppressors:

- **RB**: Critical in retinal progenitor cells, explaining the occurrence of retinoblastoma when RB1 is inactivated, but less important in many differentiated cell types.
- **p16INK4A**: Particularly important in melanocytes, contributing to the high frequency of CDKN2A inactivation in melanoma.
- **SMARCB1**: Essential in rhabdoid cells, with its loss driving highly aggressive rhabdoid tumors in early childhood.

These cell type-specific dependencies often reflect the unique developmental programs and regulatory networks operating in different cell lineages.

**Developmental Stage-Specific Requirements**

The importance of tumor suppressors can vary across developmental stages:

- **RB family proteins (RB, p107, p130)**: Show significant functional redundancy in adult tissues but have distinct roles during development.
- **p53**: Functions differently in stem cells versus differentiated cells, with more stringent activation thresholds in stem cells to allow for normal self-renewal.
- **APC**: Regulates WNT signaling differently in developing versus adult intestinal epithelium.

These developmental stage-specific effects contribute to the age distribution of different cancer types and may explain why certain hereditary cancer syndromes manifest during specific developmental windows.

**Microenvironmental Influences**

The tumor-suppressive functions of many genes are modulated by the microenvironment:

- **p53**: Its activation threshold and downstream effects are influenced by oxygen levels, nutrient availability, and inflammatory signals.
- **PTEN**: Its tumor-suppressive effects can be augmented or mitigated by the surrounding stromal cells and their secreted factors.
- **E-cadherin**: Its loss has different consequences depending on the adhesive properties of the surrounding tissue.

These microenvironmental dependencies help explain why the same genetic alterations can have different phenotypic consequences in different anatomical locations or under different physiological conditions.

**Compensatory Mechanisms and Redundancy**

The consequences of tumor suppressor loss are influenced by the availability of compensatory mechanisms:

- **RB family proteins**: Show partial functional redundancy, with p107 and p130 compensating for some but not all functions of RB.
- **p53 family members (p63, p73)**: Can activate some p53 target genes in certain contexts.
- **PTEN and INPP4B**: Both negatively regulate the PI3K pathway, providing partial redundancy.

These compensatory mechanisms contribute to the incomplete penetrance of some hereditary cancer syndromes and the tissue-specific consequences of tumor suppressor inactivation.

**Synthetic Lethality Relationships**

Tumor suppressor loss can create specific vulnerabilities through synthetic lethality relationships:

- **BRCA1/2 loss**: Creates dependency on PARP-mediated DNA repair pathways, exploited therapeutically with PARP inhibitors.
- **p53 loss**: Can sensitize cells to inhibition of ATR, CHK1, or WEE1, which are required for cell cycle checkpoints in the absence of p53.
- **SMARCB1 loss**: Creates dependency on residual SWI/SNF complex activity and specific epigenetic regulators.

These synthetic lethality relationships provide opportunities for targeted therapeutic approaches based on the specific tumor suppressor genes inactivated in a given cancer.

Understanding the cellular context and tissue specificity of tumor suppressor function is essential for interpreting the patterns of genetic alterations in different cancer types and for developing targeted therapeutic strategies based on tumor suppressor status.

### 6.1.4 Tumor Suppressors in Development and Differentiation

Beyond their role in preventing cancer, many tumor suppressor genes play critical roles in normal development and differentiation, explaining why their germline inactivation often leads to developmental abnormalities in addition to cancer predisposition.

**Developmental Functions of Key Tumor Suppressors**

Many classical tumor suppressors have essential developmental roles:

- **RB**: Regulates cell cycle exit during differentiation in multiple tissues and is essential for proper development of the hematopoietic system, nervous system, and skeletal muscle.
- **p53**: Influences embryonic implantation, neural tube development, and mesoderm differentiation.
- **APC**: Critical for axis formation, neuronal migration, and epithelial morphogenesis.
- **PTEN**: Regulates embryonic stem cell self-renewal, neuronal development, and organ size.
- **NF1**: Essential for normal development of neural crest-derived tissues and cardiac development.

The developmental phenotypes of mouse models with germline deletion of these genes often include embryonic lethality or severe developmental abnormalities, highlighting their essential roles beyond tumor suppression.

**Regulation of Stem Cell Properties**

Tumor suppressors often regulate the balance between stem cell self-renewal and differentiation:

- **p53**: Promotes differentiation of embryonic and adult stem cells, limiting self-renewal potential.
- **RB**: Facilitates cell cycle exit during differentiation and collaborates with lineage-specific transcription factors.
- **PTEN**: Restricts self-renewal of hematopoietic and neural stem cells.
- **Hippo pathway components (NF2, LATS1/2)**: Regulate organ size by controlling stem cell proliferation and differentiation.

These functions in stem cell regulation explain why tumor suppressor loss often leads to expansion of stem-like cell populations during tumorigenesis.

**Influence on Cell Fate Decisions**

Several tumor suppressors influence cell fate specification and lineage commitment:

- **NOTCH pathway regulators**: Control binary cell fate decisions in multiple tissues.
- **APC and other WNT pathway components**: Regulate cell fate specification in the intestine, skin, and other tissues.
- **RB**: Collaborates with tissue-specific transcription factors to promote terminal differentiation.
- **SWI/SNF complex components**: Facilitate activation of lineage-specific gene expression programs.

Disruption of these cell fate regulatory functions can lead to differentiation blocks that contribute to cancer development.

**Morphogenesis and Tissue Architecture**

Some tumor suppressors regulate tissue morphogenesis and architecture:

- **E-cadherin and other adhesion molecules**: Essential for epithelial tissue formation and maintenance.
- **APC**: Regulates cell migration and epithelial polarization.
- **NF2**: Controls tissue architecture through regulation of the Hippo pathway and contact inhibition.
- **PTEN**: Influences cell polarity and tissue organization.

Loss of these morphogenetic functions can disrupt tissue architecture, creating environments conducive to tumor initiation and progression.

**Developmental Syndromes Associated with Tumor Suppressor Mutations**

Germline mutations in tumor suppressor genes often cause developmental syndromes with cancer predisposition:

- **PTEN hamartoma tumor syndrome**: Caused by germline PTEN mutations and characterized by hamartomas, macrocephaly, and developmental delay, as well as increased cancer risk.
- **Gorlin syndrome**: Caused by PTCH1 mutations and characterized by developmental abnormalities including skeletal malformations and predisposition to basal cell carcinomas.
- **Tuberous sclerosis**: Caused by TSC1 or TSC2 mutations and characterized by hamartomas in multiple organs and developmental abnormalities.
- **DICER1 syndrome**: Caused by DICER1 mutations and associated with various developmental abnormalities and predisposition to rare tumors.

These syndromes highlight the dual roles of tumor suppressor genes in development and cancer prevention.

**Implications for Cancer Therapy**

Understanding the developmental roles of tumor suppressors has implications for cancer therapy:

- Therapies targeting pathways dysregulated by tumor suppressor loss must balance efficacy against potential effects on normal developmental processes.
- Developmental pathways reactivated in cancer due to tumor suppressor loss may represent therapeutic vulnerabilities.
- The differentiation-promoting functions of tumor suppressors suggest that differentiation therapy may be effective in cancers with specific tumor suppressor alterations.

By considering the developmental contexts in which tumor suppressors operate, we can gain insights into their cancer-relevant functions and identify potential therapeutic strategies based on developmental principles.

## 6.2 Mechanisms of Tumor Suppressor Inactivation

Unlike oncogenes, which drive cancer when activated or overexpressed, tumor suppressors contribute to cancer development when their function is lost or reduced. This loss of function can occur through various genetic and epigenetic mechanisms, often with different frequencies and patterns across cancer types.

### 6.2.1 Genetic Mechanisms of Inactivation

Tumor suppressor genes can be inactivated through various genetic alterations affecting their DNA sequence or copy number.

**Point Mutations**

Small-scale DNA sequence changes can disrupt tumor suppressor function:

- **Nonsense mutations**: Create premature stop codons, resulting in truncated, non-functional proteins
  - Common in TP53, RB1, APC, and many other tumor suppressors
  - Often lead to nonsense-mediated mRNA decay, eliminating the transcript

- **Frameshift mutations**: Insertions or deletions of nucleotides that are not multiples of three, altering the reading frame
  - Particularly common in genes with repetitive sequences (microsatellites)
  - Frequent in mismatch repair-deficient cancers with microsatellite instability

- **Missense mutations**: Single nucleotide changes resulting in amino acid substitutions
  - Can disrupt protein function through various mechanisms:
    - Destabilizing protein structure
    - Interfering with catalytic activity
    - Disrupting protein-protein interactions
    - Altering subcellular localization
  - Particularly important in TP53, where specific "hotspot" missense mutations not only inactivate p53 but can confer dominant-negative or gain-of-function properties

- **Splice site mutations**: Alterations at intron-exon boundaries that disrupt normal splicing
  - Can cause exon skipping, intron retention, or activation of cryptic splice sites
  - Result in aberrant proteins or nonsense-mediated mRNA decay
  - Particularly important in genes like TP53, BRCA1, and NF1

The distribution of these different types of mutations varies across tumor suppressor genes, reflecting both their sequence characteristics and the selective pressures operating during cancer evolution.

**Deletions**

Loss of genomic material containing tumor suppressor genes is a common inactivation mechanism:

- **Large-scale deletions**: Loss of substantial chromosomal regions
  - Often detected as loss of heterozygosity (LOH) in tumor samples
  - Can involve entire chromosome arms (e.g., 17p loss affecting TP53)
  - May inactivate multiple adjacent tumor suppressors simultaneously

- **Focal deletions**: Smaller deletions targeting specific genomic regions
  - Often recurring across multiple tumors, indicating selective pressure
  - Examples include deletions of 9p21 (containing CDKN2A/B) and 10q23 (containing PTEN)

- **Intragenic deletions**: Loss of portions of a gene
  - Can range from single exons to larger gene segments
  - Often result in frameshift or expression of truncated proteins
  - Particularly common in large tumor suppressor genes like NF1, BRCA1, and RB1

Modern genomic analyses have revealed that some regions containing tumor suppressor genes are preferentially deleted across multiple cancer types, suggesting their fundamental importance in constraining malignant growth.

**Structural Rearrangements**

Chromosomal rearrangements can disrupt tumor suppressor genes:

- **Translocations**: Exchange of genetic material between non-homologous chromosomes
  - Can disrupt tumor suppressor genes at breakpoints
  - May create fusion proteins that lack tumor suppressor function
  - Examples include translocations affecting NF1, CDKN2A, and PTEN

- **Inversions**: Reversal of a chromosomal segment
  - Can disrupt genes at the breakpoints
  - May separate a gene from its regulatory elements

- **Insertions**: Integration of DNA from another location
  - Can disrupt the coding sequence or regulatory elements
  - Viral insertions can inactivate tumor suppressors in virus-associated cancers

These structural variations have become increasingly recognized as important mechanisms of tumor suppressor inactivation with the advent of whole-genome sequencing technologies.

**Copy-Neutral Loss of Heterozygosity**

In some cases, a tumor suppressor allele can be lost without a change in copy number:

- **Uniparental disomy**: Loss of one parental allele followed by duplication of the remaining allele
  - Results in two identical copies of a chromosome or chromosomal region
  - Can lead to homozygosity for a mutated tumor suppressor allele
  - Particularly important when a pre-existing mutation is present

- **Gene conversion**: Non-reciprocal recombination between homologous sequences
  - Can replace a wild-type allele with a mutant one
  - Difficult to detect with standard copy number analyses

These mechanisms are important because they can inactivate tumor suppressors without the loss of genetic material that might affect adjacent essential genes.

**Mutational Patterns and Signatures**

The patterns of mutations affecting tumor suppressor genes can provide insights into their inactivation mechanisms:

- **Cancer type-specific patterns**: Different tumor types show preferences for particular inactivation mechanisms
  - Carcinogen-associated cancers often have characteristic point mutation patterns
  - Mismatch repair-deficient cancers show frequent frameshift mutations in microsatellite sequences
  - Cancers with homologous recombination deficiency show frequent deletions

- **Mutational signatures**: Specific patterns of mutations reflecting underlying mutational processes
  - Signature 1 (age-related): C>T transitions at CpG sites
  - Signature 2/13 (APOBEC): C>T and C>G mutations in specific sequence contexts
  - Signature 3: Associated with homologous recombination deficiency
  - Signatures 6/15/20/26: Associated with mismatch repair deficiency

Understanding these patterns helps identify the mechanisms driving tumor suppressor inactivation in specific cancer contexts and may inform therapeutic strategies targeting the underlying mutational processes.

### 6.2.2 Epigenetic Mechanisms of Inactivation

Beyond genetic alterations, tumor suppressor genes can be silenced through various epigenetic mechanisms that affect gene expression without changing the DNA sequence.

**DNA Methylation**

Hypermethylation of CpG islands in promoter regions is a common mechanism of tumor suppressor silencing:

- **Mechanism**: Addition of methyl groups to cytosine residues in CpG dinucleotides by DNA methyltransferases (DNMTs)
- **Effect**: Interferes with transcription factor binding and promotes recruitment of methyl-CpG binding proteins that associate with repressive complexes
- **Examples**:
  - CDKN2A (p16INK4A) in various cancers
  - MLH1 in sporadic microsatellite-unstable colorectal cancer
  - BRCA1 in sporadic breast and ovarian cancers
  - VHL in renal cell carcinoma
  - PTEN in various cancers

Promoter hypermethylation can provide a "second hit" for tumor suppressor inactivation or can silence genes without genetic alterations. The patterns of promoter hypermethylation vary across cancer types, creating distinctive "methylation signatures."

**Histone Modifications**

Changes in histone modifications can create a repressive chromatin environment at tumor suppressor loci:

- **Repressive modifications**:
  - Histone H3 lysine 27 trimethylation (H3K27me3), catalyzed by the Polycomb Repressive Complex 2 (PRC2)
  - Histone H3 lysine 9 methylation (H3K9me2/3), associated with heterochromatin formation
  - Loss of activating modifications such as H3K4me3 and histone acetylation

- **Writers, readers, and erasers**: Alterations in enzymes that add, recognize, or remove histone modifications can affect tumor suppressor expression
  - Overexpression of histone methyltransferases (e.g., EZH2)
  - Mutations in histone demethylases (e.g., KDM6A/UTX)
  - Changes in histone acetyltransferases or deacetylases

- **Examples**:
  - p16INK4A and other CDKN2A products silenced by PRC2-mediated H3K27me3
  - E-cadherin repression associated with H3K9 methylation
  - Multiple tumor suppressors affected by alterations in histone-modifying enzymes

These histone modifications often work in concert with DNA methylation to establish and maintain tumor suppressor silencing.

**Chromatin Remodeling**

ATP-dependent chromatin remodeling complexes can alter nucleosome positioning and accessibility at tumor suppressor loci:

- **SWI/SNF complex alterations**: Mutations in SWI/SNF components are common in cancer and can affect expression of tumor suppressor genes
  - SMARCB1/SNF5 mutations in rhabdoid tumors
  - SMARCA4/BRG1 mutations in various cancers
  - ARID1A mutations in ovarian, endometrial, and other cancers

- **Nucleosome positioning**: Changes in nucleosome occupancy, particularly at transcription start sites, can impede transcription initiation
  - Occlusion of transcription factor binding sites
  - Interference with assembly of the transcriptional machinery

- **Higher-order chromatin structure**: Changes in chromatin looping and nuclear organization can affect gene expression
  - Disruption of enhancer-promoter interactions
  - Repositioning of tumor suppressor loci to repressive nuclear compartments

These changes in chromatin structure can create heritable states of tumor suppressor silencing that persist through cell divisions.

**Non-coding RNAs**

Various non-coding RNAs can regulate tumor suppressor expression:

- **microRNAs (miRNAs)**: Small non-coding RNAs that typically repress gene expression by binding to complementary sequences in target mRNAs
  - Overexpression of miRNAs targeting tumor suppressor transcripts
  - Examples: miR-21 targeting PTEN, miR-155 targeting TP53INP1

- **Long non-coding RNAs (lncRNAs)**: Can influence gene expression through various mechanisms
  - Recruitment of chromatin-modifying complexes to specific loci
  - Competition for miRNA binding (acting as "sponges")
  - Modulation of mRNA stability or translation
  - Examples: ANRIL regulating the CDKN2A/B locus, HOTAIR recruiting PRC2 to target genes

- **Circular RNAs (circRNAs)**: Covalently closed RNA molecules that can function as miRNA sponges or regulate transcription
  - Can affect tumor suppressor expression by sequestering miRNAs that target tumor suppressors

These RNA-based mechanisms add another layer of complexity to the epigenetic regulation of tumor suppressor genes.

**Alterations in RNA Processing**

Post-transcriptional mechanisms can affect tumor suppressor expression:

- **Alternative splicing**: Generation of splice variants with altered function
  - Production of dominant-negative isoforms
  - Skipping of exons containing functional domains
  - Examples: TP53 splice variants, MDM2 splice variants

- **mRNA stability**: Changes affecting the half-life of tumor suppressor transcripts
  - Alterations in AU-rich element (ARE) binding proteins
  - Changes in non-sense mediated decay efficiency
  - Modifications affecting RNA structure

- **Translation efficiency**: Mechanisms affecting protein synthesis from tumor suppressor mRNAs
  - Changes in upstream open reading frames (uORFs)
  - Alterations in RNA secondary structure
  - Modifications affecting ribosome recruitment

These post-transcriptional mechanisms can reduce tumor suppressor protein levels even when the gene is transcribed normally.

**Interplay Between Genetic and Epigenetic Mechanisms**

Genetic and epigenetic mechanisms often interact in tumor suppressor inactivation:

- **Mutations in epigenetic regulators**: Genetic alterations affecting the machinery that establishes or maintains epigenetic patterns
  - DNMT3A mutations in hematologic malignancies
  - TET2 mutations affecting DNA demethylation
  - Histone modifier mutations (EZH2, KMT2C/D, etc.)

- **Epigenetic silencing as a "second hit"**: Promoter hypermethylation providing the second hit in the two-hit hypothesis
  - Common in hereditary cancer syndromes like Lynch syndrome and BRCA1/2-associated cancers

- **Epigenetic field defects**: Widespread epigenetic alterations creating a permissive environment for subsequent genetic changes
  - Age-associated epigenetic drift
  - Inflammation-associated epigenetic changes
  - Environmental exposure-related epigenetic alterations

Understanding this interplay is essential for comprehending the complex process of tumor suppressor inactivation during carcinogenesis.

### 6.2.3 Haploinsufficiency and Dominant-Negative Effects

While complete inactivation of both alleles is the classical model for tumor suppressor loss, alternative mechanisms involving partial loss of function can also contribute to carcinogenesis.

**Haploinsufficiency**

Haploinsufficiency occurs when a single functional copy of a tumor suppressor gene is insufficient to maintain normal cellular function:

- **Mechanism**: Loss or mutation of one allele reduces the total amount of functional protein below a critical threshold
- **Dose-dependent tumor suppressors**: Genes whose function is sensitive to expression level
  - PTEN: 50% reduction in expression can promote tumorigenesis
  - p53: Mice with reduced p53 dosage show intermediate cancer susceptibility
  - NF1: Haploinsufficiency contributes to certain aspects of neurofibromatosis
  - DPC4/SMAD4: Haploinsufficiency may contribute to juvenile polyposis syndrome

- **Cellular consequences**:
  - Subtle changes in signaling pathway dynamics
  - Altered thresholds for cellular responses
  - Increased susceptibility to additional oncogenic events

- **Implications**:
  - Challenges the classical two-hit model for some tumor suppressors
  - Suggests that even heterozygous mutations or deletions can contribute to cancer risk
  - May explain the earlier onset or increased severity of cancers in individuals with germline mutations

Haploinsufficiency provides a mechanism by which partial loss of tumor suppressor function can contribute to the early stages of carcinogenesis, potentially creating a state of increased susceptibility to subsequent oncogenic events.

**Dominant-Negative Effects**

Some mutant tumor suppressor proteins can actively interfere with the function of the remaining wild-type protein:

- **Mechanism**: Mutant protein forms complexes with wild-type protein, impairing its function
  - Common in proteins that function as dimers or multimers
  - Can achieve functional inactivation without requiring mutation or loss of the second allele

- **Examples**:
  - p53: Certain missense mutations produce stable proteins that can oligomerize with wild-type p53 and impair its transcriptional activity
  - BRCA1: Some mutations produce truncated proteins that interfere with wild-type BRCA1 function
  - IDH1/IDH2: Mutations producing neomorphic enzymes that generate oncometabolites

- **Consequences**:
  - Functional inactivation of the wild-type protein
  - Potential gain of novel functions not present in either wild-type or null states
  - Altered cellular responses to stresses or therapies

- **Implications**:
  - Single mutations can have more profound effects than simple loss of one allele
  - Therapeutic strategies may need to target the dominant-negative protein
  - Genetic testing and cancer risk assessment must consider the specific mutations present

Dominant-negative effects explain why certain mutations in tumor suppressor genes are particularly oncogenic and may confer worse prognosis than simple deletions or truncating mutations.

**Continuum of Functional Impact**

The functional consequences of tumor suppressor alterations exist on a continuum:

- **Complete loss of function**: Classical two-hit inactivation, resulting in absence of functional protein
- **Partial loss of function**: Hypomorphic mutations that reduce but do not eliminate protein function
- **Dominant-negative effects**: Mutations that actively interfere with remaining wild-type protein
- **Gain of function**: Novel oncogenic activities not present in the wild-type protein

The specific functional impact of a tumor suppressor alteration influences its contribution to cancer development and progression, as well as potential therapeutic vulnerabilities.

**Interactions with Genetic Background**

The consequences of partial tumor suppressor inactivation can be influenced by genetic background:

- **Modifier genes**: Variations in other genes that affect the penetrance or expressivity of tumor suppressor mutations
  - Explain variable phenotypes in individuals with identical tumor suppressor mutations
  - May affect the likelihood of second-hit events or the consequences of haploinsufficiency

- **Gene-gene interactions**: Synthetic effects between multiple tumor suppressor alterations
  - Combined haploinsufficiency of interacting tumor suppressors
  - Cooperative effects between alterations in different pathway components

- **Tissue-specific factors**: Elements of the cellular context that influence the consequences of tumor suppressor alterations
  - Availability of redundant pathways
  - Tissue-specific enhancers or repressors
  - Cell type-specific stress responses

Understanding these interactions is essential for predicting cancer risk in individuals with tumor suppressor mutations and for developing personalized prevention and treatment strategies.

### 6.2.4 Inactivation Patterns Across Cancer Types

The mechanisms and patterns of tumor suppressor inactivation vary considerably across cancer types, reflecting differences in tissue biology, environmental exposures, and evolutionary constraints.

**Cancer Type-Specific Inactivation Mechanisms**

Different tumor types show preferences for particular inactivation mechanisms:

- **Colorectal cancer**:
  - APC: Predominantly truncating mutations
  - TP53: Mix of missense mutations and 17p deletions
  - MLH1: Frequently silenced by promoter methylation in microsatellite-unstable tumors

- **Breast cancer**:
  - BRCA1/2: Germline mutations or promoter methylation
  - TP53: High frequency of missense mutations in basal/triple-negative subtype
  - PTEN: Mixture of mutations, deletions, and epigenetic silencing

- **Lung cancer**:
  - TP53: High frequency of G→T transversions in smokers
  - RB1: Predominant inactivation in small cell lung cancer
  - CDKN2A: Frequent homozygous deletion in non-small cell lung cancer

- **Hematologic malignancies**:
  - Frequent mutations in epigenetic regulators (DNMT3A, TET2, ASXL1)
  - TP53: Less frequent than in solid tumors, but associated with poor prognosis
  - Chromosomal deletions affecting multiple tumor suppressors (5q, 7q, 17p)

These patterns reflect both the underlying mutational processes active in different tissues and the selective pressures operating during cancer evolution.

**Mutation Frequency and Distribution**

The frequency and distribution of tumor suppressor alterations vary across cancer types:

- **Universally altered pathways**: Despite different specific genes being altered, certain pathways are almost universally disrupted
  - Cell cycle regulation (RB pathway)
  - DNA damage response (p53 pathway)
  - Growth factor signaling (RTK-RAS-PI3K pathways)

- **Cancer type-defining alterations**: Some tumor suppressor alterations are characteristic of specific cancer types
  - APC in colorectal cancer
  - VHL in clear cell renal cell carcinoma
  - NF2 in meningiomas and schwannomas
  - SMARCB1 in rhabdoid tumors

- **Mutational burden and tumor suppressor alterations**: Relationship between overall mutation rate and tumor suppressor inactivation patterns
  - Hypermutated cancers often have mutations in DNA repair genes (MSH2, MLH1, POLE)
  - Cancers with low mutation burden may rely more on epigenetic silencing or large-scale deletions

These patterns provide insights into the evolutionary trajectories of different cancer types and may inform strategies for early detection and prevention.

**Temporal Patterns of Inactivation**

Tumor suppressor genes are inactivated at different stages of cancer development:

- **Early events**: Alterations occurring during initiation or early progression
  - APC mutations in colorectal adenomas
  - CDKN2A inactivation in melanocytic nevi
  - VHL inactivation in renal cell carcinoma
  - NF1 loss in neurofibromas

- **Late events**: Alterations associated with progression to invasive or metastatic disease
  - TP53 mutations in progression from adenoma to carcinoma in colorectal cancer
  - PTEN loss in prostate cancer progression
  - CDH1 (E-cadherin) loss in invasive lobular breast carcinoma

- **Branched evolution**: Different tumor regions or metastases acquiring distinct tumor suppressor alterations
  - Heterogeneity in TP53 mutations across tumor regions
  - Different patterns of chromosome loss in metastases versus primary tumors

Understanding these temporal patterns helps identify opportunities for early intervention and reveals the evolutionary constraints operating during cancer progression.

**Clinical Correlations and Therapeutic Implications**

Patterns of tumor suppressor inactivation correlate with clinical features and therapeutic responses:

- **Prognostic associations**: Certain tumor suppressor alterations associated with prognosis
  - TP53 mutations: Generally adverse prognostic factor
  - BRCA1/2 mutations: Associated with better response to platinum chemotherapy and PARP inhibitors
  - PTEN loss: Associated with resistance to various targeted therapies

- **Predictive biomarkers**: Tumor suppressor status predicting response to specific therapies
  - MSH2/MLH1 deficiency: Response to immune checkpoint inhibitors
  - BRCA1/2 mutations: Sensitivity to PARP inhibitors
  - SMARCB1 loss: Potential sensitivity to EZH2 inhibitors

- **Synthetic lethality opportunities**: Therapeutic vulnerabilities created by tumor suppressor loss
  - PARP inhibitors in BRCA-deficient cancers
  - ATR inhibitors in TP53-mutant cancers
  - mTOR inhibitors in tuberous sclerosis complex-mutant tumors

These clinical correlations highlight the importance of accurately assessing tumor suppressor status for patient stratification and treatment selection.

## 6.3 Key Tumor Suppressor Genes

While numerous tumor suppressor genes have been identified, several stand out for their frequent involvement in human cancers, their central roles in critical cellular processes, and their therapeutic implications. This section examines the structure, function, and cancer relevance of key tumor suppressor genes.

### 6.3.1 TP53: Guardian of the Genome

The TP53 gene, encoding the p53 protein, is the most frequently mutated tumor suppressor in human cancer, with alterations in approximately 50% of all malignancies. Its central role in coordinating cellular responses to various stresses has earned it the title "guardian of the genome."

**Structure and Domains**

The p53 protein consists of several functional domains:

- **N-terminal transactivation domains (TAD1 and TAD2)**: Mediate interactions with the transcriptional machinery and negative regulators like MDM2
- **Proline-rich domain**: Contains PXXP motifs involved in protein-protein interactions
- **Central DNA-binding domain**: Recognizes specific DNA sequences in target gene promoters
  - Contains most cancer-associated mutations
  - Highly conserved across species
- **Oligomerization domain**: Facilitates formation of functional tetramers
- **C-terminal regulatory domain**: Subject to numerous post-translational modifications that regulate p53 function

This modular structure allows p53 to integrate multiple signals and interact with diverse partners to coordinate complex cellular responses.

**Normal Functions**

p53 coordinates responses to various cellular stresses:

- **Cell cycle arrest**: Induces p21 (CDKN1A) expression to arrest cells in G1 or G2 phase, allowing time for DNA repair
- **DNA repair**: Facilitates repair through multiple mechanisms:
  - Transcriptional activation of repair genes
  - Direct interactions with repair proteins
  - Regulation of chromatin accessibility at damage sites
- **Apoptosis**: Induces programmed cell death when damage is severe
  - Activates transcription of pro-apoptotic genes (BAX, PUMA, NOXA)
  - Represses anti-apoptotic genes (BCL2, survivin)
  - Directly interacts with mitochondrial proteins to promote cytochrome c release
- **Senescence**: Induces permanent cell cycle arrest in response to telomere erosion, oncogene activation, or severe damage
- **Metabolism**: Regulates metabolic pathways to support adaptation to stress
  - Modulates glycolysis, oxidative phosphorylation, and glutaminolysis
  - Regulates antioxidant defense systems
- **Stemness and differentiation**: Promotes differentiation and limits stem cell self-renewal

These diverse functions collectively prevent the propagation of cells with damaged genomes or inappropriate growth signals.

**Regulation of p53**

Given its potent effects, p53 activity is tightly regulated:

- **MDM2 and MDMX**: Primary negative regulators
  - MDM2 is an E3 ubiquitin ligase that targets p53 for proteasomal degradation
  - MDMX enhances MDM2 activity
  - p53 transcriptionally activates MDM2, creating a negative feedback loop
- **Post-translational modifications**: Numerous modifications affect p53 stability, localization, and activity
  - Phosphorylation (by ATM, ATR, CHK1, CHK2) in response to DNA damage
  - Acetylation (by p300/CBP, PCAF) enhancing transcriptional activity
  - Methylation, ubiquitination, SUMOylation, neddylation
- **Cofactors and binding partners**: Influence p53 target gene selection and activity
  - ASPP family proteins direct p53 to apoptotic gene targets
  - YAP1 enhances p53-mediated apoptosis
  - iASPP inhibits p53 apoptotic function
- **Non-coding RNAs**: microRNAs and long non-coding RNAs that modulate p53 expression or activity

This multilayered regulation ensures that p53 is activated appropriately in response to cellular stresses while remaining restrained under normal conditions.

**Alterations in Cancer**

p53 is inactivated through various mechanisms in cancer:

- **Missense mutations**: Most common alteration
  - Concentrated in the DNA-binding domain
  - "Hotspot" mutations (R175, G245, R248, R249, R273, R282)
  - Can exhibit dominant-negative effects by forming mixed tetramers with wild-type p53
  - Some mutants demonstrate oncogenic gain-of-function activities
- **Truncating mutations**: Nonsense or frameshift mutations resulting in shortened proteins
- **Deletions**: Loss of the TP53 locus, often as part of chromosome 17p deletion
- **Viral inactivation**: Proteins from oncogenic viruses bind and inactivate p53
  - HPV E6 protein targets p53 for degradation
  - SV40 large T antigen binds and inactivates p53
- **Overexpression of negative regulators**: MDM2 or MDMX amplification or overexpression
- **Altered cofactor function**: Mutations in genes encoding p53 cofactors or modifiers

The specific pattern of p53 alterations varies across cancer types, with implications for prognosis and therapeutic response.

**Clinical Significance**

p53 status has important clinical implications:

- **Prognostic value**: p53 mutations generally associated with worse outcomes
  - Reduced response to chemotherapy and radiation
  - Increased metastatic potential
  - Genomic instability promoting aggressive phenotypes
- **Li-Fraumeni syndrome**: Hereditary cancer predisposition caused by germline TP53 mutations
  - High lifetime risk of multiple cancer types (breast cancer, sarcomas, brain tumors, adrenocortical carcinoma)
  - Early onset cancers
  - Multiple primary tumors
- **Therapeutic targeting**:
  - MDM2 inhibitors (e.g., nutlin-3, idasanutlin) for wild-type p53 tumors
  - Approaches to restore function to mutant p53 (e.g., APR-246)
  - Synthetic lethal approaches exploiting vulnerabilities created by p53 loss
  - Cell cycle checkpoint inhibitors (WEE1, CHK1) in p53-deficient backgrounds

Understanding p53 status is increasingly important for patient stratification and treatment selection across multiple cancer types.

### 6.3.2 RB1: Master Regulator of the Cell Cycle

The RB1 gene, encoding the retinoblastoma protein (pRb), was the first tumor suppressor gene to be cloned and serves as a paradigmatic example of the two-hit hypothesis. It plays a central role in regulating cell cycle progression, particularly the transition from G1 to S phase.

**Structure and Domains**

The pRb protein contains several functional domains:

- **N-terminal domain**: Contains regions involved in protein-protein interactions
- **Pocket domain**: Consists of A and B pocket subdomains separated by a spacer region
  - Mediates interactions with E2F transcription factors and viral oncoproteins
  - Most mutations cluster in this region
- **C-terminal domain**: Contains multiple phosphorylation sites and additional protein interaction motifs

This structure enables pRb to function as a hub for protein interactions that regulate cell cycle progression.

**Normal Functions**

pRb serves as a critical regulator of various cellular processes:

- **Cell cycle control**: Primary function is regulation of G1/S transition
  - Binds and inhibits E2F transcription factors in hypophosphorylated state
  - Represses genes required for DNA replication and cell cycle progression
  - Forms repressive complexes with histone deacetylases (HDACs) and other chromatin modifiers
- **Differentiation**: Promotes terminal differentiation in multiple tissues
  - Interacts with tissue-specific transcription factors
  - Stabilizes differentiation-associated gene expression programs
  - Facilitates permanent cell cycle exit during differentiation
- **Genome stability**: Maintains chromosomal integrity
  - Regulates chromatin structure at repetitive regions
  - Prevents DNA re-replication
  - Influences DNA damage responses
- **Apoptosis regulation**: Context-dependent effects on cell death
  - Generally anti-apoptotic during normal development
  - Can promote apoptosis in specific contexts, including cancer therapy
- **Metabolism**: Influences cellular metabolic pathways
  - Affects glucose uptake and utilization
  - Regulates mitochondrial function

These diverse functions position pRb as a central coordinator of cell proliferation, differentiation, and survival decisions.

**Regulation of pRb**

pRb activity is regulated through various mechanisms:

- **Phosphorylation**: Primary regulatory mechanism
  - Hypophosphorylated pRb is active, binding E2Fs and repressing their target genes
  - Sequential phosphorylation by cyclin D-CDK4/6 and cyclin E-CDK2 inactivates pRb during G1/S transition
  - Dephosphorylation by phosphatases (e.g., PP1, PP2A) reactivates pRb during mitotic exit
- **Acetylation**: Affects pRb stability and function
- **Protein-protein interactions**: Various binding partners influence pRb activity
  - Viral oncoproteins (SV40 large T antigen, HPV E7, adenovirus E1A) bind and inactivate pRb
  - Chromatin modifiers enhance pRb-mediated gene repression
  - Tissue-specific transcription factors direct pRb to specific gene targets
- **Expression level**: Regulated by microRNAs and other mechanisms

This regulation ensures that pRb activity is coordinated with cell cycle progression and developmental signals.

**Alterations in Cancer**

RB1 is inactivated through various mechanisms in different cancer types:

- **Biallelic inactivation**: Common in retinoblastoma and some other cancers
  - Mutations: Nonsense, frameshift, splice site, and missense mutations
  - Deletions: Large or small deletions affecting part or all of the gene
  - Promoter methylation: Epigenetic silencing (less common)
- **Functional inactivation**: More common in carcinomas
  - Hyperactivation of cyclin D-CDK4/6 through various mechanisms
    - CCND1 amplification or overexpression
    - CDK4 amplification
    - Loss of p16INK4A (CDKN2A)
  - Viral oncoprotein binding (HPV E7 in cervical cancer)
  - Alterations in phosphatases that regulate pRb phosphorylation status

The frequency and mechanism of RB pathway disruption vary across cancer types, with some showing direct RB1 inactivation while others target upstream or downstream pathway components.

**Clinical Significance**

RB1 status has important clinical implications:

- **Hereditary retinoblastoma**: Caused by germline RB1 mutations
  - ~1:20,000 live births
  - High risk of bilateral retinoblastoma
  - Increased risk of secondary malignancies, particularly osteosarcoma
- **Diagnostic marker**: RB1 loss is characteristic of certain cancer types
  - Small cell lung cancer
  - Retinoblastoma
  - Some bladder cancers
- **Therapeutic implications**:
  - CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) effective in tumors with intact RB1
  - RB1 loss associated with resistance to these inhibitors
  - RB1 status may influence response to other therapies, including chemotherapy

Understanding RB1 and overall RB pathway status is increasingly important for treatment decisions, particularly regarding CDK4/6 inhibitors in breast cancer and other malignancies.

### 6.3.3 BRCA1 and BRCA2: Guardians of Genomic Integrity

BRCA1 and BRCA2 are critical tumor suppressor genes involved in DNA repair, particularly homologous recombination repair of double-strand breaks. Germline mutations in these genes confer high lifetime risks of breast, ovarian, and other cancers.

**Structure and Domains**

**BRCA1**:
- **N-terminal RING domain**: Mediates E3 ubiquitin ligase activity in complex with BARD1
- **Coiled-coil domain**: Facilitates interaction with PALB2
- **C-terminal BRCT domains**: Phosphopeptide-binding modules that mediate interactions with phosphorylated proteins in DNA damage response
- **Nuclear localization signals**: Direct BRCA1 to the nucleus
- **Exon 11**: Large central exon encoding regions that interact with RAD51 and other proteins

**BRCA2**:
- **N-terminal transcriptional activation domain**
- **BRC repeats**: Eight conserved motifs that bind RAD51
- **DNA-binding domain**: Binds single-stranded DNA
- **C-terminal RAD51-binding domain**: Distinct from BRC repeats
- **Nuclear localization signals**: Direct BRCA2 to the nucleus

These structural features enable BRCA1 and BRCA2 to coordinate complex processes involved in DNA repair and genome maintenance.

**Normal Functions**

BRCA1 and BRCA2 have multiple roles in maintaining genomic integrity:

**BRCA1 functions**:
- **Homologous recombination repair**: Promotes repair of double-strand breaks through:
  - DNA end resection in partnership with CtIP
  - Recruitment of repair factors to damage sites
  - Regulation of RAD51 loading onto single-stranded DNA
- **Checkpoint activation**: Promotes cell cycle arrest in response to DNA damage
  - Phosphorylated by ATM and ATR in response to damage
  - Facilitates activation of checkpoint kinases CHK1 and CHK2
- **Transcriptional regulation**: Influences expression of genes involved in DNA repair and cell cycle control
- **Chromatin remodeling**: Interacts with chromatin-modifying enzymes to facilitate repair
- **Centrosome regulation**: Influences centrosome duplication and mitotic spindle formation
- **Protection of stalled replication forks**: Prevents degradation of nascent DNA at stalled forks

**BRCA2 functions**:
- **Homologous recombination repair**: Critical mediator of RAD51 filament formation
  - Binds single-stranded DNA
  - Loads RAD51 onto DNA, displacing RPA
  - Stabilizes RAD51 nucleoprotein filaments
- **Protection of stalled replication forks**: Prevents MRE11-mediated degradation of nascent DNA
- **Mitotic spindle assembly checkpoint**: Ensures accurate chromosome segregation
- **Cytokinesis**: Proper completion of cell division

These functions collectively maintain genomic stability, preventing the accumulation of mutations and chromosomal aberrations that can drive cancer development.

**Regulation of BRCA1 and BRCA2**

BRCA1 and BRCA2 activity is regulated through various mechanisms:

- **Phosphorylation**: Multiple kinases phosphorylate BRCA1 in response to DNA damage or during cell cycle progression
  - ATM and ATR phosphorylate BRCA1 following DNA damage
  - CDKs phosphorylate BRCA1 during cell cycle progression
- **Ubiquitination**: Affects BRCA1 function and stability
  - Auto-ubiquitination through BRCA1-BARD1 E3 ligase activity
  - Ubiquitination by other E3 ligases affecting stability
- **Protein-protein interactions**: Complex network of interactions in response to DNA damage
  - BRCA1-A, BRCA1-B, and BRCA1-C complexes with distinct functions
  - BRCA2-PALB2-BRCA1 interactions critical for homologous recombination
- **Cell cycle-dependent expression**: Levels peak in S phase when homologous recombination is most active
- **Subcellular localization**: Regulated nuclear import/export and localization to specific nuclear foci

This regulation ensures that BRCA1 and BRCA2 activities are coordinated with cell cycle progression and DNA damage responses.

**Alterations in Cancer**

BRCA1 and BRCA2 are inactivated through various mechanisms:

- **Germline mutations**: Associated with hereditary breast and ovarian cancer syndrome
  - Frameshift, nonsense, and splice site mutations most common
  - Large genomic rearrangements (deletions/duplications)
  - Missense variants of uncertain significance (VUS) complicate clinical interpretation
- **Somatic mutations**: Less common than germline but occur in sporadic cancers
  - Similar spectrum to germline mutations
  - Second hits in tumors from germline mutation carriers
- **Promoter hypermethylation**: Particularly of BRCA1 in sporadic breast and ovarian cancers
- **Gene expression changes**: Reduced expression without genetic or epigenetic alterations
- **"BRCAness"**: Functional deficiency in homologous recombination despite intact BRCA1/2
  - Mutations in other homologous recombination genes (PALB2, RAD51C, etc.)
  - Alterations in upstream regulators

The spectrum and frequency of BRCA1/2 alterations vary across cancer types, with the highest frequencies in breast, ovarian, pancreatic, and prostate cancers.

**Clinical Significance**

BRCA1/2 status has significant clinical implications:

- **Hereditary cancer risk**:
  - BRCA1 mutations: 60-85% lifetime breast cancer risk, 40-60% ovarian cancer risk
  - BRCA2 mutations: 40-85% breast cancer risk, 10-30% ovarian cancer risk
  - Increased risk of pancreatic, prostate, and other cancers
- **Risk-reducing interventions**:
  - Prophylactic surgeries (mastectomy, salpingo-oophorectomy)
  - Enhanced surveillance
  - Chemoprevention options
- **Therapeutic implications**:
  - Sensitivity to PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib)
  - Enhanced response to platinum-based chemotherapy
  - Potential sensitivity to ATR inhibitors and other agents targeting DNA damage response
- **Genetic testing and counseling**:
  - Complex variant interpretation
  - Psychological and family implications
  - Cascade testing of relatives

The identification of BRCA1/2 mutations has profound implications for affected individuals and their families, influencing cancer risk assessment, surveillance, prevention, and treatment decisions.

### 6.3.4 PTEN: A Phosphatase with Broad Tumor Suppressive Functions

PTEN (Phosphatase and tensin homolog) is a lipid and protein phosphatase that negatively regulates the PI3K-AKT-mTOR pathway and has numerous additional functions. It is one of the most frequently altered tumor suppressors across human cancers.

**Structure and Domains**

The PTEN protein contains several functional domains:

- **N-terminal phosphatase domain**: Contains the catalytic site responsible for dephosphorylating phosphatidylinositol-3,4,5-trisphosphate (PIP3)
- **C2 domain**: Mediates membrane binding
- **C-terminal tail**: Contains multiple phosphorylation sites that regulate PTEN stability and activity
- **PDZ-binding motif**: Mediates interactions with PDZ domain-containing proteins
- **Nuclear localization signals**: Direct PTEN to the nucleus

This structure enables PTEN to function both as a lipid phosphatase at the plasma membrane and as a protein phosphatase and scaffolding protein in various cellular compartments.

**Normal Functions**

PTEN has diverse functions in maintaining cellular homeostasis:

- **PI3K pathway regulation**: Primary tumor suppressive function
  - Dephosphorylates PIP3 to PIP2, antagonizing PI3K activity
  - Inhibits AKT activation and downstream signaling
  - Regulates mTORC1 and mTORC2 complex activity
- **Protein phosphatase activity**: Dephosphorylates protein substrates
  - Focal adhesion kinase (FAK)
  - Shc
  - Various receptor tyrosine kinases
- **Regulation of cell migration and polarity**:
  - Affects cytoskeletal dynamics
  - Influences directional migration
  - Maintains epithelial architecture
- **Genomic stability**:
  - Nuclear functions independent of phosphatase activity
  - Regulation of chromosomal integrity
  - DNA damage responses
- **Cell cycle regulation**:
  - Controls G1/S transition
  - Influences stability of cell cycle regulators
- **Stem cell self-renewal**:
  - Restricts neural stem cell proliferation
  - Limits hematopoietic stem cell expansion
  - Regulates pluripotency of embryonic stem cells

These diverse functions position PTEN as a central regulator of cellular processes frequently dysregulated in cancer.

**Regulation of PTEN**

PTEN activity is regulated through multiple mechanisms:

- **Transcriptional regulation**:
  - p53 activates PTEN transcription
  - NOTCH1 represses PTEN expression
  - Various microRNAs target PTEN mRNA
- **Post-translational modifications**:
  - Phosphorylation affects stability, activity, and localization
  - Ubiquitination regulates degradation
  - SUMOylation influences nuclear localization
  - Acetylation modulates activity
- **Protein-protein interactions**:
  - PTEN-associated complexes affect localization and function
  - Competitive binding of regulatory proteins
- **Subcellular localization**:
  - Membrane, cytoplasmic, and nuclear pools with distinct functions
  - Dynamic shuttling between compartments

These regulatory mechanisms ensure that PTEN function is precisely controlled in response to cellular conditions and developmental signals.

**Alterations in Cancer**

PTEN is inactivated through various mechanisms in cancer:

- **Mutations**: Diverse types affecting different functional domains
  - Nonsense and frameshift creating truncated proteins
  - Missense affecting phosphatase activity or stability
  - Splice site disrupting normal transcript processing
- **Deletions**: Monoallelic or biallelic loss
  - Large deletions of chromosome 10q
  - Focal deletions targeting the PTEN locus
- **Epigenetic silencing**:
  - Promoter hypermethylation
  - Histone modifications repressing transcription
- **Post-translational mechanisms**:
  - Increased degradation through ubiquitin-proteasome pathway
  - Sequestration in inappropriate subcellular compartments
- **Competitive inhibition**:
  - PTEN pseudogene (PTENP1) transcripts sequestering PTEN-targeting microRNAs
  - Proteins that interfere with PTEN function

PTEN alterations are particularly common in prostate cancer, endometrial cancer, glioblastoma, and melanoma, but occur across almost all cancer types.

**Clinical Significance**

PTEN status has important clinical implications:

- **PTEN Hamartoma Tumor Syndrome (PHTS)**:
  - Caused by germline PTEN mutations
  - Includes Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, and others
  - Characterized by multiple hamartomas and increased cancer risk
  - Macrocephaly, developmental delay, and other manifestations
- **Prognostic marker**:
  - PTEN loss generally associated with worse outcomes
  - Marker of aggressive disease in prostate cancer
  - Associated with reduced survival in various cancers
- **Therapeutic implications**:
  - Predictor of response to PI3K/AKT/mTOR pathway inhibitors
  - Resistance factor for RTK-targeted therapies (e.g., HER2 inhibitors, EGFR inhibitors)
  - Potential synthetic lethal interactions with P